Cas no 150399-23-8 (Pemetrexed disodium)
Pemetrexed disodium Chemical and Physical Properties
Names and Identifiers
-
- Pemetrexed disodium
- 2-[4-[2-(4-Amino-2-oxo-3,5,7-triazabicyclo[4.3.0]nona-3,8,10-trien-9-yl)ethyl]benzoyl]aminopentanedioic acid disodium salt
- Pemetrexed
- Alimt
- ALIMTA
- AMN-107
- LY231514 disodium
- LY-231514 disodium
- Nilotinib
- PeMetexed DisodiuM
- Pemetrexed (disodium)
- Pemetrexed Dinatrium
- PEMETREXED SODIUM
- Pemwtrexed Disodium
- N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt
- LY-231514
- AliMta disodiuM
- LY 231514 disodiuM
- Rolazar
- Tifolar
- 2PKU919BA9
- Alimta (TN)
- Pemetrexed disodium [USAN]
- Pemetrexed disodium (USAN)
- Pemetrexed sodium hydrate
- Pemetrexed disodium hydrate
- disodium (2S)-2-({4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}amino)pentanedioate
- Pemetrexed disodium salt
- LY 231514
- N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]
- disodium N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamate
- PEMETREXED SODIUM SALT [MI]
- NCGC00167486-01
- CHEMBL2360464
- UNII-2PKU919BA9
- HMS3264H07
- AC-1326
- CS-W004541
- L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
- HMS3715P06
- N-(4-[2-(2-Amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5yl)ethyl]benzoyl)-L-Glutamic Acid Disodium Salt
- Disodium, Pemetrexed
- N-(4-[2-(2-Amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-Glutamic Acid Disodium Salt
- SCHEMBL18348
- PEMETREXED DISODIUM [ORANGE BOOK]
- DTXSID8046660
- N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2.3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt
- disodium N-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
- Tox21_112487
- PEMETREXED DISODIUM (USP-RS)
- PEMETREXED DISODIUM [USP-RS]
- PEMETREXED DISODIUM (USP MONOGRAPH)
- AKOS025392176
- Sodium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate
- Almita
- N-[4[2-(-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamate sodium salt
- disodium;(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
- EX-A836
- LY231514 DISODIUM SALT
- Pemetrexed sodium salt
- LY 231,514
- 150399-23-8
- Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
- CCG-213071
- CAS-150399-23-8
- N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamic Acid Disodium Salt
- LY-231514 DISODIUM SALT
- PEMETREXED DISODIUM [WHO-DD]
- NYDXNILOWQXUOF-GXKRWWSZSA-L
- disodium (2S)-2-((4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)amino)pentanedioate
- BDBM50512141
- sodium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate
- CCG-221272
- D03828
- s1135
- CHEBI:63722
- DTXCID6026660
- AKOS025149477
- A809041
- sodium(S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate
- Pemetrexed Disodium is known as a Thymidylate synthase inhibitor.
- DISODIUM N-(P-(2-((2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2,3-D)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-L-GLUTAMATE
- PEMETREXED DISODIUM [USP MONOGRAPH]
- KS-5001
- Pemetrexed for system suitability
- L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, sodium salt (1:2)
- LY231514
-
- MDL： MFCD07779402
- Inchi： 1S/C20H21N5O6.2Na/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;/q;2*+1/p-2/t13-;;/m0../s1
- InChI Key： NYDXNILOWQXUOF-GXKRWWSZSA-L
- SMILES： [Na+].[Na+].O=C1C2=C(N=C(N)N1)NC=C2CCC1C=CC(C(N[C@H](C(=O)[O-])CCC(=O)[O-])=O)=CC=1
Computed Properties
- Exact Mass: 471.11300
- Monoisotopic Mass: 471.113
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 7
- Heavy Atom Count: 33
- Rotatable Bond Count: 7
- Complexity: 737
- Covalently-Bonded Unit Count: 3
- Defined Atom Stereocenter Count: 1
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 193
Experimental Properties
- Color/Form: Powder
- Melting Point: 255-265°C (dec.)
- Boiling Point: No data available
- Flash Point: No data available
- Solubility: 生物體外In Vitro:H2O≥ 100 mg/mL(212.15 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
- PSA: 196.92000
- LogP: -1.03090
- Vapor Pressure: No data available
Pemetrexed disodium Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501
- Hazard Category Code： R36/38;R60;R61;R68
- Safety Instruction： 36/37/39-53
-
Hazardous Material Identification：
- Safety Term：S36/37/39;S53
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
- Risk Phrases：R36/38; R60; R61; R68
Pemetrexed disodium Customs Data
- HS CODE：2933990090
- Customs Data：
China Customs Code:
2933990090Overview:
2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Pemetrexed disodium Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| MedChemExpress | HY-10820A-10mM*1mLinWater |
Pemetrexed disodium |
150399-23-8 | 99.95% | 10mM*1mLinWater |
￥605 | 2023-07-26 | |
| MedChemExpress | HY-10820A-10mg |
Pemetrexed disodium |
150399-23-8 | 99.79% | 10mg |
￥550 | 2025-04-16 | |
| MedChemExpress | HY-10820A-50mg |
Pemetrexed disodium |
150399-23-8 | 99.79% | 50mg |
￥750 | 2025-04-16 | |
| MedChemExpress | HY-10820A-100mg |
Pemetrexed disodium |
150399-23-8 | 99.79% | 100mg |
￥1250 | 2025-04-16 | |
| MedChemExpress | HY-10820A-200mg |
Pemetrexed disodium |
150399-23-8 | 99.79% | 200mg |
￥2100 | 2025-04-16 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | P129841-250mg |
Pemetrexed disodium |
150399-23-8 | ≥99% | 250mg |
￥704.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | P129841-50mg |
Pemetrexed disodium |
150399-23-8 | ≥99% | 50mg |
￥221.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | P129841-1g |
Pemetrexed disodium |
150399-23-8 | ≥99% | 1g |
￥2158.90 | 2023-09-01 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R010196-250mg |
Pemetrexed disodium |
150399-23-8 | 99% | 250mg |
￥675 | 2024-05-25 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R010196-50mg |
Pemetrexed disodium |
150399-23-8 | 99% | 50mg |
￥211 | 2024-05-25 |
Pemetrexed disodium Suppliers
Audited Supplier
Audited Supplier
Pemetrexed disodium Related Literature
-
Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
-
Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
-
Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
-
Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
Additional information on Pemetrexed disodium
Recent Advances in Pemetrexed Disodium (150399-23-8) Research: A Comprehensive Review
Pemetrexed disodium (CAS: 150399-23-8) is a well-established antifolate chemotherapeutic agent primarily used in the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). As a multi-targeted antifolate, it inhibits several key enzymes in the folate pathway, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). Recent research has focused on optimizing its therapeutic efficacy, overcoming resistance mechanisms, and exploring novel combination therapies.
A 2023 study published in the Journal of Medicinal Chemistry investigated the structural modifications of pemetrexed disodium to enhance its cellular uptake and reduce drug resistance. The researchers synthesized several analogs with improved membrane permeability while maintaining the compound's target specificity. Their findings demonstrated that certain modifications to the glutamate moiety could significantly increase intracellular concentrations without compromising the drug's inhibitory effects on TS and DHFR.
In the field of combination therapies, a recent phase II clinical trial (NCT04889066) evaluated the efficacy of pemetrexed disodium in combination with immune checkpoint inhibitors for advanced NSCLC patients. The 2024 results showed a promising overall response rate of 42% with manageable toxicity profiles, suggesting this combination could become a new standard of care for selected patient populations. The study also identified potential biomarkers for predicting treatment response, including TS expression levels and tumor mutational burden.
Pharmacokinetic research has made significant strides in understanding the optimal dosing strategies for pemetrexed disodium. A 2024 population pharmacokinetic analysis published in Cancer Chemotherapy and Pharmacology revealed that body surface area-adjusted dosing might not be the most accurate method for all patient populations. The study proposed alternative dosing algorithms based on renal function and genetic polymorphisms in folate pathway genes, which could lead to more personalized treatment approaches.
Emerging research has also explored the potential of pemetrexed disodium in other cancer types. A preclinical study demonstrated significant activity against certain subtypes of bladder cancer, particularly those with specific genetic alterations in the folate metabolism pathway. These findings, published in Molecular Cancer Therapeutics in early 2024, suggest potential expansion of pemetrexed disodium's clinical applications beyond its current indications.
On the formulation front, researchers have developed novel nanoparticle-based delivery systems for pemetrexed disodium to improve tumor targeting and reduce systemic toxicity. A recent breakthrough published in Advanced Drug Delivery Systems showed that albumin-bound pemetrexed nanoparticles achieved 3-5 times higher tumor accumulation compared to conventional formulations in animal models, while significantly reducing bone marrow toxicity.
Resistance mechanisms to pemetrexed disodium continue to be an active area of investigation. A comprehensive genomic analysis published in Nature Cancer in 2023 identified several novel resistance pathways, including upregulation of alternative nucleotide synthesis routes and changes in drug transporter expression. These findings are guiding the development of next-generation antifolates and combination strategies to overcome resistance.
In conclusion, recent research on pemetrexed disodium (150399-23-8) has advanced our understanding of its mechanisms of action, optimized its clinical use, and expanded its potential applications. The development of novel analogs, improved formulations, and rational combination therapies continues to enhance the therapeutic potential of this important anticancer agent. Future directions include further personalization of treatment based on molecular profiling and the exploration of pemetrexed disodium in novel therapeutic contexts.
150399-23-8 (Pemetrexed disodium) Related Products
- 869791-42-4(N-Methyl Pemetrexed)
- 137281-23-3(Pemetrexed)
- 155405-81-5(Pemetrexed Methyl Ester)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
